Drug Trial Radar · NCT07889284
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
336
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- ScandiBio Therapeutics ABIndustry
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine for 4 weeks.
Conditions
- Gout Disease
Interventions
Combined metabolic activatorsDrug
A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study.
Collagen and maltodextrinOther
As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo.Time frame: 4 weeks
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye)
Alanya Training and Research Hospital
Antalya, Turkey (Türkiye)
Atatürk University Research Hospital
Erzurum, Turkey (Türkiye)
Erzurum City Hospital
Erzurum, Turkey (Türkiye)
Eskişehir Osmangazi University Faculty of Medicine Hospital
Eskişehir, Turkey (Türkiye)
Göztepe Prof. Dr. Süleyman Yalçın City Hospital
Istanbul, Turkey (Türkiye)
Istanbul University-Cerrahpaşa Faculty of Medicine Hospital
Istanbul, Turkey (Türkiye)
Kanuni Sultan Süleyman Training and Research Hospital
Istanbul, Turkey (Türkiye)
Kartal Dr. Lütfi Kırdar City Hospital
Istanbul, Turkey (Türkiye)
Koç University Hospital
Istanbul, Turkey (Türkiye)
Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital
Istanbul, Turkey (Türkiye)
Sultan 2nd Abdülhamid Han Training and Research Hospital
Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.